Key facts
- Immunochina Pharmaceuticals’s last known valuation is $215.3M (Sep 2020).
- It has raised $45.0M; the latest was Later Stage VC in Jan 2025.
- Notable investors include Cowin Capital, Legend Capital, SJ Jiacheng Investment Management, GF Qianhe, ZGC Science City — 21 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 21 names
- ·Watchlist + deal alerts for Immunochina Pharmaceuticals
- ·The full record, as it builds
Funding rounds
No funding rounds for Immunochina Pharmaceuticals are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Immunochina Pharmaceuticals
Developer of gene cell medicine technology intended for malignant tumor treatment. The company is devoted to the development of CAR-T technology and immune cell therapy in cancer and immunology research, helping researchers and practitioners find effective ways to combat hematological malignancies.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2015
- Employees
- 100
- Website
- imunopharm.com/
- Ownership
- Privately Held (backing)
Immunochina Pharmaceuticals doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Immunochina Pharmaceuticals shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Immunochina Pharmaceuticals in its N-PORT filings yet. We sweep new filings monthly.